Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

Dimensional Fund Advisors LP raised its stake in Inozyme Pharma, Inc. (NASDAQ:INZY) by 117.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,064 shares of the company’s stock after buying an additional 205,417 shares during the period. Dimensional Fund Advisors LP owned about 0.61% of Inozyme Pharma worth $1,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in INZY. Meeder Asset Management Inc. purchased a new stake in shares of Inozyme Pharma in the 2nd quarter worth approximately $68,000. American Century Companies Inc. lifted its position in shares of Inozyme Pharma by 11.0% in the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after purchasing an additional 5,673 shares during the period. Rhumbline Advisers lifted its position in shares of Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Inozyme Pharma by 16.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after purchasing an additional 26,464 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in shares of Inozyme Pharma in the 2nd quarter worth approximately $76,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Trading Up 5.1 %

NASDAQ INZY opened at $5.18 on Friday. The company has a fifty day simple moving average of $5.16 and a two-hundred day simple moving average of $5.08. The stock has a market cap of $324.94 million, a P/E ratio of -3.55 and a beta of 1.51. Inozyme Pharma, Inc. has a 12-month low of $2.69 and a 12-month high of $7.80. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). On average, analysts forecast that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

INZY has been the subject of several research reports. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a research note on Monday, September 30th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Tuesday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Inozyme Pharma in a research note on Thursday, August 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.14.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.